Scholarlink

<p>Class A G protein-coupled receptors (GPCRs) constitute the majority of the clinical GPCR targets and are implicated in a wide range of neuropsychiatric disorders. Dimerization of class A GPCRs often introduces unique modes of allosteric modulation, leading to the reprogramming of the downstream signaling relative to individual protomers. In this review, we highlight the experimental evidence and pharmacological properties of class A GPCR dimers involved in mental disorders. We further elucidate the molecular basis of dimer assembly and activation through a comprehensive structural analysis of currently available class A GPCR dimers. Current strategies and therapeutic potential of dimer-specific targeting are also discussed. Together, these insights provide a framework for understanding class A GPCR dimer function and pave the way for the development of dimer-informed therapeutics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanistic and therapeutic insights into class A GPCR dimers in neuropsychiatric disorders

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Zhaojing Wang,
  • Linlin Wang,
  • Shicheng Zhang

摘要

Class A G protein-coupled receptors (GPCRs) constitute the majority of the clinical GPCR targets and are implicated in a wide range of neuropsychiatric disorders. Dimerization of class A GPCRs often introduces unique modes of allosteric modulation, leading to the reprogramming of the downstream signaling relative to individual protomers. In this review, we highlight the experimental evidence and pharmacological properties of class A GPCR dimers involved in mental disorders. We further elucidate the molecular basis of dimer assembly and activation through a comprehensive structural analysis of currently available class A GPCR dimers. Current strategies and therapeutic potential of dimer-specific targeting are also discussed. Together, these insights provide a framework for understanding class A GPCR dimer function and pave the way for the development of dimer-informed therapeutics.